Production (Stage)
ARYx Therapeutics, Inc.
ARYX
$0.00
$0.000.00%
OTC PK
| 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | 09/30/2009 | |
|---|---|---|---|---|---|
| Net Income | 54.67% | 17.51% | 5.81% | -6.24% | -53.88% |
| Total Depreciation and Amortization | -13.33% | -22.05% | -7.24% | -1.55% | 9.39% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -51.81% | -35.96% | -14.67% | -16.40% | 4.01% |
| Change in Net Operating Assets | -42.27% | 92.80% | 83.36% | 71.30% | 86.10% |
| Cash from Operations | 49.23% | 49.37% | 36.69% | 22.67% | 7.37% |
| Capital Expenditure | 59.06% | 70.62% | 79.02% | 78.11% | 82.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 41.83% | 432.83% | 221.78% | 584.43% | 279.93% |
| Cash from Investing | 44.11% | 480.18% | 216.94% | 449.13% | 243.71% |
| Total Debt Issued | 529.10% | -- | -- | -- | -88.89% |
| Total Debt Repaid | -250.22% | -568.40% | -171.16% | -29.98% | 48.16% |
| Issuance of Common Stock | -63.49% | -63.30% | -62.60% | -93.83% | -53.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -138.04% | -138.04% | -291.07% | -- | -115.38% |
| Cash from Financing | -59.53% | -93.36% | -84.62% | -107.24% | -60.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 72.14% | 53.42% | 55.35% | -46.79% | -440.22% |